Introduction
Cyclooxygenase-2 (Cox-2), also known as prostaglandin (PG) H synthase catalyzes the rate-limiting steps in the formation of prostaglandin endoperoxides (Smith and Marnett, 1991) . Various prostanoids function as extracellular or intracellular messengers (Smith and Dew, 1996) . Classical examples such as PGF 2a and PGE 2 are secreted and mediate signal transduction via the activation of plasma membrane G-protein coupled receptors (Coleman et al., 1994) , which may lead to adenyl cyclase activation and to a cAMP increase. Cyclooxygenase-2 induction after activation of macrophages is well established (Reddy and Herschman, 1994; Hempel et al., 1994; Lee et al., 1992; O`Sullivan et al., 1992) . LPS/IFN-g stimulation is a standard physiological activation protocol for macrophages leading to Cox-2 expression, prostaglandin formation, and in turn to a cAMP increase. Recently, we have shown that LPS/IFN-g prestimulation of macrophages confers resistance to cytotoxic doses of exogenously added NO-donors (BruÈ ne et al., 1996) . Furthermore Cox-2 has been identi®ed as a necessary component in the signaling cascade leading to protection (von Knethen and BruÈ ne., 1997).
The Cox-2 gene is overexpressed in several proliferative pathological conditions such as rheumatoid arthritis and colon carcinoma (Sano et al., 1992 (Sano et al., , 1995 Eberhart et al., 1994) . As the chronic use of nonsteroidal anti-in¯ammatory drugs such as aspirin reduce the incidence of colon cancer (Giovannucci et al., 1995) and anti-in¯ammatory drugs such as sulindac block tumorigenesis in experimental murine models of colon cancer (Reddy et al., 1987) , it is assumed that Cox-2 plays a causative role in tumor initiation and/or promotion. Prostanoid synthesis is often enhanced in tumors (Rigas et al., 1993) , and nonsteroidal antiin¯ammatory drugs inhibit the growth of certain established tumor cell lines in vitro and in athymic mice (Peterson, 1983) . Moreover, evidence that Cox-2 is involved in tumor initiation and/or promotion is inferable from studies in the murine system. Mating tumor suppressor APC gene knock-out mice which spontaneously develop intestinal polyps, with Cox-2 knock-out mice resulted in the suppression of polyp formation. In addition, polyp formation was attenuated by Cox-2 speci®c pharmacological inhibitors (Oshima et al., 1996) . These studies strongly imply that Cox-2 expression is required for the development of cancer, i.e. colon cancer.
Overexpression of Cox-2 in a gastrointestinal epithelial cell line is associated with inhibition of apoptosis (Tsujii and DuBois, 1995) and alterations in the cell cycle (DuBois et al., 1996) . Because apoptotic resistant cells may be prone to mutagenic events, inhibition of apoptosis is a potential underlying explanation for Cox-induced tumorigenesis. The signal transducing events responsible for the functional role of Cox-2 in protecting cells from apoptosis and thus promoting tumorigenesis, remain elusive.
In our study, we present evidence that macrophage preactivation attenuated DNA fragmentation induced by the DNA damaging agents cisplatin and etoposide in close association with a down-regulated p53 response. Our experiments imply cAMP-mediated gene activation as the predominant underlying protective principle.
Results

Etoposide and cisplatin induced macrophage apoptosis
To induce apoptosis by etoposide and cisplatin, two commonly used apoptosis inducing agents (Shaulian et al., 1997; Fulda et al., 1997; Eischen et al., 1997; Chen et al., 1996) , we ®rst determined their dose eect ecacy. Therefore we exposed RAW 264.7 macrophages for 8 h to increasing concentrations of etoposide (10 ± 500 mM) and cisplatin (5 ± 100 mM), which have been described as eective concentrations in tumor therapy (Sandler, 1997; Ramanthan and Belani, 1997) . Apoptosis was determined using the diphenylamine assay, which allows to measure the DNA content in the cytoplasm (DNA fragments) compared to the uncleaved DNA content of the nucleus (McConkey et al., 1989) . Apoptotic cells showed an increased level of DNA in the cytosol due to the diusion of small DNA fragments, which occur as a result of the endonucleasespeci®c DNA-fragmentation in the nucleus (Wyllie, 1980) . The DNA content of the cytosol and the nucleus was then quantitated using the diphenylamine reagent which leads to colour development that is detected using an ELISA-reader (Burton, 1956) .
Etoposide revealed a minor response at 10 ± 50 mM, while intermediate fragmentation was initiated with 100 ± 200 mM. A dose of 500 mM etoposide promoted strong DNA degradation with fragmentation values around 50% (Figure 1a ). Controls that were not exposed to the DNA damaging agents consistently showed fragmentation below 10%.
Similar results were obtained with cisplatin. Cisplatin at concentrations of 5 and 10 mM was non eective in RAW macrophages, while massive fragmentation between 40 ± 50% was achieved at doses of 25 ± 100 mM ( Figure 1a ). To assure apoptotic versus necrotic cell death LDH release assays were performed (Vassault, 1983) . LDH is released from cells only, when plasma membrane integrity is destroyed by necrotic rapture (Trump et al., 1997; Hale et al., 1996; Majno and Joris, 1995) . Results from the LDH release assays underscored plasma membrane integrity during our incubations with chemotherapeutic agents (Figure 1b) .
For further investigations we selected concentrations of chemotherapeutica which gave a reliable DNA fragmentation response in RAW 264.7 macrophages. Therefore, etoposide was used at 500 mM, while cisplatin was employed at a concentration of 50 mM.
Activation of RAW 264.7 macrophages by LPS, IFN-g and NAME blocked etoposide-and cisplatin-induced apoptosis Previously we noticed that activation of RAW 264.7 macrophages for 15 h with the combination of LPS/ IFN-g/NAME prior to the addition of cytotoxic doses of NO-donors conferred resistance via a Cox-2 dependent mechanism (von Knethen and BruÈ ne, 1997). Therefore, we examined the eectiveness of prestimulation to the apoptotic action of cisplatin and etoposide. Cellular preactivation signi®cantly reduced etoposide-and cisplatin-initiated DNA fragmentation to values around 10 ± 15% (Figure 2a ).
For these experiments the speci®c iNOS-inhibitor NAME had to be included in order to block endogenous NO formation in response to LPS/IFN-g because an active NO-synthase otherwise would suce to cause apoptotic alterations in RAW 264.7 macrophages (Messmer et al., 1995) .
Accumulation of the tumor suppressor p53 was observed in close association with chemotherapeuticainduced apoptosis (Figure 2b ). This is in line with the well established response of cells towards DNA damaging agents (Clarke et al., 1993; Lowe et al., 1993a,b; Gottlieb et al., 1994) . Etoposide (500 mM) and cisplatin (50 mM) promoted p53 accumulation in RAW macrophages within a 4 h incubation period. p53 ocassionally was expressed at minor levels in unstimulated controls.
Preactivation of macrophages with LPS/IFN-g NAME not only suppressed DNA fragmentation but also abrogated the etoposide-and cisplatin-induced p53 response. LPS/IFN-g/NAME itself did not evoke p53 accumulation.
Our results corroborate p53 accumulation and DNA fragmentation during etoposide-and cisplatin-induced apoptosis and revealed ecient termination of these responses by macrophage preactivation.
Further studies attempted to delineate protective signaling mechanisms following LPS/IFN-g/NAME preactivation. Experiments are based on the observa- tion that macrophage preactivation resulted in cyclooxygenase-2 expression in close association with prostaglandin-E 2 production which in turn elevated cAMP in a self-regulatory feed-back loop (Pang and Hoult, 1997; Karim et al., 1997; Bornfeldt et al., 1997; DiBattista et al., 1997) . It has been shown by others that cAMP-mediated signal transduction constitutes a relevant factor for resistance of human myeloma cells against radiation (Yang et al., 1996) and is responsible for cancer cell growth (Tortora et al., 1997a,b) . Therefore, we envisioned to mimic protection by incubating macrophages with lipophilic cAMP-analogs.
Cyclic-AMP confers macrophage protection towards chemotherapeutic agents
In a ®rst set of experiments we exposed RAW 264.7 macrophages for 1 h to lipophilic cAMP-analogs such as 8-Br-cAMP and db-cAMP prior to initiation of apoptosis by cisplatin. Cell-permeable cAMP-analogs were employed at concentrations of 0.5 and 1 mM. Cisplatin (50 mM) evoked 50% DNA fragmentation during an 8 h incubation period ( Figure 3a ). Neither preincubation with 8-Br-cAMP nor the application of db-cAMP reduced endonuclease-mediated DNA degradation under these conditions. In line, we noticed unaltered p53 accumulation by cisplatin in samples that received lipophilic cAMPanalogs beforehand (Figure 3b ). Similar results were obtained when using etoposide (data not shown). DNA fragmentation and p53 accumulation were indistinguishable in all samples irrespective their pretreatment with lipophilic-cAMP derivatives. Obviously, lipophilic cAMP-analogs did not protect towards chemotherapeutic agents when incubated for 1 h, only.
Figure 2 LPS/IFN-g/NAME preactivation attenuated DNA fragmentation and p53 accumulation in response to chemotherapeutica. RAW 264.7 macrophages (2610 6 cells for DNA fragmentation; 5610 6 cells for Western blots) were prestimulated with a combination of LPS (10 mg/ml), IFN-g (100 U/ml) and NAME (1 mM) for 15 h (abbreviated; LIN) or remained untreated before cisplatin or etoposide at the indicated concentrations were added for an additional 8 h (DNA fragmentation) or 4 h (p53 accumulation) period. (a) DNA fragmentation was assessed by the diphenylamine assay, while (b) p53 was determined by Western blot analysis as described under Materials and methods. Data are mean values +s.d. of three individual experiments (P*40.02 versus controls). The Western blot is representative of three similar experiments In further experiments we extended the preexposure period with lipophilic cAMP-analogs to 15 h. The long preincubation period of macrophages with either 1 mM 8-Br-cAMP or 1 mM db-cAMP conferred protection against etoposide-mediated DNA fragmentation. DNA degradation induced by 500 mM etoposide served as a 100% control value. Relative to the etoposide control, pretreatment with lipophilic cAMP-analogs or with LPS/IFN-g/NAME reduced fragmentation by 70 ± 80% (Figure 4a, left panel) . Results with cisplatin-initiated fragmentation were comparable. In proportion to cisplatin which served as the 100% control value, fragmentation drastically was reduced by 8-Br-cAMP-, db-cAMP-or LPS/IFN-g/NAME-prestimulation (Figure 4a, right panel) .
Prolonged preincubation of macrophages with cell permeable cAMP-derivatives blocked DNA fragmentation by 70 ± 80%. A comparable reduction was obtained by LPS/IFN-g/NAME preactivation. We then sought to correlate down-regulated DNA fragmentation to the chemotherapeutic-elicited p53 response (Figure 4b ). Western blot analysis revealed the absence of p53 in controls (Figure 4b , lane 9) which were not exposed to DNA damaging agents and showed massive protein accumulation within 4 h after treatment with 50 mM cisplatin or 500 mM etoposide (Figure 4b, lanes 1 and 5) .
Addition of lipophilic cAMP-analogs for 15 h reduced the chemotherapeutica-promoted p53 response. In these experiments db-cAMP turned out to be a more eective suppressor than 8-Br-cAMP. For comparison we showed reduced p53 immunoreactivity following LPS/IFN-g/NAME prestimulation for 15 h in parallel ( Figure 4B, lanes 4 and 8) .
Apparently, suppression of chemotherapeutica-induced DNA fragmentation and p53 accumulation by lipophilic cAMP-analogs required a long lasting preincubation period. We concluded that cAMP mediates protection by gene induction. To further prove this hypothesis we used a decoy oligonucleotide approach.
CRE decoy oligonucleotides attenuated LPS/IFN-g/ NAME-and liphophilic cAMP-mediated protection
To demonstrate the transcriptional relevance in liphophilic cAMP-mediated protection a decoy approach was performed. Oligonucleotides containing a CRE site were transfected into macrophages to scavange the activated transcription factor CREB. This method has successfully been used to inhibit NF-kB mediated transcription (Schmedtje et al., 1997; Roshak et al., 1996; Sharma et al., 1996) .
For our experiments we employed oligonucleotides containing a CRE-binding site (decoy-approach) or, alternatively, oligonucleotides with an altered base sequence (control-approach). Macrophages, exposed to 3 mM of¯uorescence-labeled oligonucleotides for 24 h revealed roughly 50% of all cells to be positively aected (Figure 5a ). Following oligonucleotide labeling, cells were exposed for 15 h to 1 mM db-cAMP or LPS/IFN-g NAME in order to promote protection towards chemotherapeutica.
Thereafter, apoptotic DNA fragmentation was initiated with cisplatin (50 mM) or etoposide (500 mM) (Figure 5b ). Addition decoy oligonucleotides reversed protection, thus allowing roughly 30% DNA fragmentation in response to chemotherapeutica. In contrast, control oligonucleotides did not counteract the inhibitory principle evoked by lipophilic cAMP-or LPS/IFN-g/NAME-treatment. In addition decoy oligonucleotides also restored p53 accumulation in response to cisplatin (Figure 5c 6 cells for Western blots) were prestimulated for 15 h with 1 mM 8-bromo-cAMP, 1 mM dibutyryl-cAMP with a combination of LPS (10 mg/ml), IFN-g (100 U/ml) and NAME (1 mM In corroboration with other reports we noticed typical apoptotic alterations in response to cisplatin and etoposide such as DNA fragmentation and accumulation of the tumor suppressor protein p53 (Zamble and Lippard, 1995; McDonnell et al., 1995; Kaufmann and Kaufman, 1993) . Moreover, initiation of other apoptotic accompanying signals, exempli®ed by the activation of caspases, seem inherent to the action of cisplatin or etoposide (Eischen et al., 1997) .
The tumor suppressor p53 is recognized as the guardian of the genome and seems indispensable for activation of the apoptotic program induced by DNAdamaging chemotherapeutic agents (Levine, 1997; McDonnell et al., 1995) . The (wild type) wtp53 protein exerts an array of biochemical activities among the best documented are cell cycle arrest and apoptosis (Canman and Kastan, 1995; Donehower and Bradley, 1993) . For macrophages we established p53 to be at least in part involved in conveying the apoptotic initiating activity of nitric oxide (Messmer and BruÈ ne, 1996) . A dependence on wtp53 function for cisplatin sensitivity in several systems is established (Perego et al., 1996; Zamble and Lippard, 1995; McDonnell et al., 1995) and suggests that the inability of macrophages to upregulate p53 is linked to suppression of apoptosis. The competence to block p53 accumulation in response to cisplatin and etoposide is initiated by LPS/IFN-g/ NMMA-pretreatment. Previously, we demonstrated that macrophage preactivation by LPS/IFN-g/NMMA protected towards NO-mediated apoptosis by promoting cyclooxygenase-2 expression (von Knethen and BruÈ ne, 1997) . In extension of these experiments we now established that LPS/IFN-g/NMMA-preactivation abrogated apoptosis by DNA damaging agents as well. Enforced expression of cyclooxygenase-2 in the sequence of events leading to colorectal cancer is unquestionable and genetic evidence links cyclooxygenase-2 to tumorigenesis (Tsujii and DuBois, 1995; . The employment of cyclooxygenase-2 selective inhibitors as therapeutic agents for colorectal polyposis and cancer join cyclooxygenase-derived metabolites and deregulation of apoptosis together (Sheng et al., 1997) . Expression of cyclooxygenase-2 in macrophages is associated with prostaglandin E 2 formation which in turn may increase intracellular cAMP (Quinn et al., 1996; Zhang et al., 1995) . Hypothetically we followed the idea that cAMP promotes protection. The action of cAMP-elevating agents in suppressing apoptosis is known for several system, i.e. for hepatocytes, neutrophils, or natural killer cell mediated cytotoxicity (Walker et al., 1997; Fladmark et al., 1997; Torgersen et al., 1997) . However, mechanistic considerations on cAMPmediated signal transduction in conferring resistance Figure 5 CRE decoy oligonucleotides attenuated cAMPmediated protection. (a) Uptake of¯uorescent labeled CRE decoy oligonucleotides (3 mM, 24 h) into RAW 264.7 macrophages (1610 6 cells) was assessed by immuno¯uorescence microscopy. Left panel bright®eld microscopy, right panel same detail in immuno¯uorescence microscopy. (b) RAW 264.7 macrophages (1610 6 cells) were incubated with decoy or control oligonucleotides for 24 h as described under Materials and methods. After changing the medium cells were prestimulated with 1 mM 8-bromo-cAMP, 1 mM dibutyryl-cAMP or with a combination of LPS (10 mg/ml), IFN-g (100 U/ml) and NAME (1 mM) (abbreviated; LIN) for 15 h as indicated. Afterwards DNA fragmentation was initiated by the addition of 500 mM etoposide or 50 mM cisplatin. Quantitatation was by the diphenylamine assay as described under Materials and methods. Data are mean values +s.d. of three individual experiments (P* 40.02 versus control oligonucleotides). (c) Following prestimulation as described under (b), p53 accumulation was determined by Western blot analysis as described under Materials and methods after the addition of cisplatin or etoposide at the indicated concentrations. The Western blot is representative of three similar experiments cAMP and protection from apoptosis A von Knethen et al are largely unknown. Under in¯ammatory conditions increased levels of cAMP elevating prostaglandins acting via adenyl cyclase may eciently balance apoptotic initiating and counteracting pathways in cells of the monocyte/macrophage lineage. The assumed involvement of cAMP during protection was endorsed by applying lipophilic cAMP-analogs that blocked DNA fragmentation and p53 accumulation in response to chemotherapeutica. Cellular responses towards cAMP are mediated by activation of cAMPdependent protein kinases (Houslay and Milligan, 1997) . The inactive kinase holoenzyme dissociates after the binding of cAMP and liberates the catalytic subunit which in turn phosphorylates multiple substrates. Phosphorylation may aect structural components or enzyme activities, or alternatively, may promote alterations in gene transcription by phosphorylation and activation of the transcription factor CREB (Frank and Greenberg, 1994; Nakajima et al., 1997) . Phosphorylated CREB binds to the promoter region of various genes and initiates transcription (Kwok et al., 1994; Arias et al., 1994) . The protective eect of cAMP-mediated signal transduction has been described for human cancer cell growth (Tortora et al, 1997a,b) , radiation resistance of melanoma cells (Yang et al., 1996) and FAS-mediated apoptotsis of primary hepatocytes (Fladmark et al., 1997) , although it has been shown to act proapoptotic in other systems (Ruchaud et al., 1997; Ivanov et al., 1997) . Our study veri®es the protective mechanism to convey resistance towards chemotherapeutic agents by LPS/IFN-g/ NAME or lipophilic cAMP-analog pretreatment. Con®rmation came from the successful use of decoy oligonucleotides with their ability to scavenge activated CREB, thereby abrogating protection and allowing p53 accumulation. The observation that decoy oligonucleotides allowed roughly 30% DNA fragmentation in response to cisplatin or etoposide instead of completely restoring the apoptotic inducing ability of DNA damaging compounds is compatible when considering a transfection eciency with decoy oligonucleotides of roughly 50% in macrophages. Although cAMPresponsive gene products remain elusive, they seem to participate in the regulation of p53. We assume as a further working hypothesis that in response to cAMPinitiated gene transcription a protein factor, either directly or indirectly, would aect the steady state level of p53. Loss of p53 function by transfection of a dominant negative p53 mutant into the intrinsically sensitive human ovarian A2780 cell line has been shown to induce resistance to anticancer drugs, including cisplatin (Gallagher et al., 1997) . Moreover, the selection of genetic suppressor elements from a retroviral library expressing random fragments of human or murine TPp53 cDNA confers cisplatin resistance (Gallagher et al., 1997) . In close analogy to our results these data indicate a strong association between p53 function and chemotherapy resistance. With the notion that p53 is regulated by multiple phosphorylation, proteosomal degradation or by altering its mRNA stability and/or translational rate our experiments will address these possibilities under conditions of cAMP-evoked protection.
Understanding transducing mechanisms that confer inducible resistance towards chemotherapeutic agents in immune competent cells such as macrophages by cAMP-mediated gene activation may help to activate these pathways selectively prior to tumor therapy and may increase our understanding in eliminating these components, thereby restoring chemosensitivity.
Materials and methods
Materials
Diphenylamine, bovine serum albumin (BSA), and LPS (E. coli serotype 0127 : B8) were purchased from Sigma, Deisenhofen, Germany. L-N G -nitroarginine methyl ester (L-NAME) was from Alexis, GruÈ nberg, Germany. Recombinant murine interferon-g 8-bromo-cAMP and dibutyrylcAMP were provided by Boehringer Mannheim, Mannheim, Germany. RPMI 1640, cell culture supplements, and fetal calf serum were ordered from Biochrom, Berlin, Germany. Cisplatin and etoposide were obtained from Sigma, Dreieich, Germany. The p53-antibody (PAb248) was kindly provided by H Stahl, Homburg/Saar, Germany. All other chemicals were of the highest grade of purity and commercially available.
Cell culture
The mouse monocyte/macrophage cell line RAW 264.7 was maintained in RPMI 1640 supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin and 10% heat-inactivated fetal calf serum (complete RPMI). All experiments were performed using complete RPMI.
Drug treatment
Etoposide was dissolved in DMSO while cisplatin was supplied from a DMF stock solution. 8-bromo-cAMP and dibutyryl-cAMP were dissolved in bidistilled water. Appropriate vehicle controls were performed.
Quantitation of DNA fragmentation
DNA fragmentation was measured with the diphenylamine assay as previously reported (McConkey et al., 1989) . Brie¯y, following incubations cells were scraped o the culture plates, resuspended in 250 ml 10 mM Tris, 1 mM EDTA, pH 8.0 (TE-buer) and incubated with an additional volume lysis-buer (5 mM Tris, 20 mM EDTA, pH 8.0, 0.5% Triton X-100) for 30 min at 48C. After lysis, the intact chromatin (pellet) was separated from DNA fragments (supernatant) by centrifugation for 15 min at 13 000 g. Pellets were resuspended in 500 ml TE-buer and samples were precipitated by adding 500 ml 10% trichloroacetic acid at 48C. Samples were pelleted at 4000 r.p.m. for 10 min and the supernatant was removed. After addition of 300 ml 5% trichloroacetic acid, samples were boiled for 15 min. DNA contents were quantitated using the diphenylamine reagent (Burton, 1956) . The percentage of DNA fragmentation was calculated as the ratio of the DNA content in the supernatant to the amount in the pellet.
Measurement of lactate dehydrogenase (LDH) release
The integrity of the plasma membrane was determined by measuring LDH activity released into the culture medium. LDH activity was monitored following the oxidation of NADH as the decrease in absorbance at 334 nm. Reactions were carried out in a potassium phosphate buer (40 mM K 2 HPO 4 , 10 mM KH 2 PO 4 , pH 7.5), containing 0.24 mM NADH and 0.62 mM pyruvate. The percentage of LDH released was de®ned as the ratio of LDH activity in the supernatant to the sum of the LDH amount released plus the activity measured in the cell lysate. 
Cell survival
Following drug treatment the viability of RAW 264.7 cells was determined by the trypan blue dye exclusion assay.
Transfection
RAW 264.7 cells were transiently transfected with CRE oligonucleotides, containing the CRE-consensus site derived from the c-fos promoter (Sassone-Corsi et al., 1988) and an unrelated oligonucleotide as a control. 5'-terminal¯uorescein labeled oligonucleotides were stabilized by phosphothiorate linkages (Eurogentec, Seraing, Belgium). CRE sequence in use (consensus sequence underlined):
5'-GAT ATT GCC TGA CGT CAG AG-3' 3'-TAA CGG ACT GCA GTC TCT CG-5'
One day before transfection cells were seeded at a density of 1610 6 cells/well into 6-well-plates. Oligonucleotides (3 mM) were added 24 h prior to cell stimulation. After changing the medium, cell stimulation was performed as indicated. Transfection eciency was determined by counting labeled cells by¯uorescence-microscopy.
Western blot analysis
Cell lysis was achieved with lysis buer (50 mM Tris, 5 mM EDTA, 150 mM NaCl, 0.5% Nonidet-40, 1 mM phenylsulfonylmethyl¯uorid, pH 8.0) and sonication (Branson soni®er; 20 s, duty cycle 100%, output control 60%), followed by centrifugation (10 000 g, 5 min), and protein determination with the Lowry method (Lowry et al., 1951) . Protein (150 mg) was resolved on 10% polyacrylamide gels and blotted onto nitrocellulose sheets basically following standard methodology (Laemmli, 1970) . Equal loading and correct protein transfer to nitrocellulose was routinely quantitated by Ponceau S staining. Filters were incubated with the anti-p53 antibody (1 : 250) overnight at 48C. Horse-radish peroxidase (HRP)-conjugated polyclonal antibodies (1 : 5000) were used for enhanced chemiluminescence (ECL) detection (Amersham).
Statistical analyses
Each experiment was performed at least three times and statistical analysis was performed using the two tailed Student's t-test. Normal distribution of all data is assured. Otherwise representative data are shown.
